ImmusanT Overview

  • Year Founded
  • 2010

Year Founded

  • Status
  • Out of Business

  • Employees
  • 15

Employees

  • Latest Deal Type
  • Out of Business

ImmusanT General Information

Description

Developer of therapeutic vaccines intended to treat people with autoimmune diseases. The company's platform provides a precision medicine approach to restoring immune tolerance across a range of diseases, including celiac disease and type 1 diabetes, thereby enabling clinicians to improve diagnosis and medical management of autoimmune diseases.

Contact Information

Ownership Status
Out of Business
Financing Status
Formerly VC-backed
Corporate Office
  • One Kendall Square
  • Building 700
  • Cambridge, MA 02139
  • United States
+1 (617)
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Vertical(s)
Corporate Office
  • One Kendall Square
  • Building 700
  • Cambridge, MA 02139
  • United States
+1 (617)

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

ImmusanT Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
5. Out of Business 08-Jan-2021 Completed Out of Business
4. Later Stage VC (Series C) 11-Sep-2018 Completed Clinical Trials - Phase 2
3. Later Stage VC (Series C) 14-Nov-2017 Completed Clinical Trials - Phase 2
2. Early Stage VC (Series B) 30-Dec-2014 $12.8M $12.8M Completed Clinical Trials - Phase 1
1. Early Stage VC (Series A) 13-Dec-2011 Completed Startup
To view ImmusanT’s complete valuation and funding history, request access »

ImmusanT Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series C
Series B
Series A 108,698,304 $0.000100 8% $0.23 $0.23 1x $0.23 28.87%
To view ImmusanT’s complete cap table history, request access »

ImmusanT Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of therapeutic vaccines intended to treat people with autoimmune diseases. The company's platform provides a p
Drug Discovery
Cambridge, MA
15 As of 2019

Plymouth Meeting, PA
 

New York, NY
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

ImmusanT Competitors (65)

One of ImmusanT’s 65 competitors is Inovio Pharmaceuticals, a Corporation company based in Plymouth Meeting, PA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Inovio Pharmaceuticals Corporation Plymouth Meeting, PA
Cognition Therapeutics Formerly VC-backed New York, NY
Sorrento Therapeutics Formerly VC-backed San Diego, CA
Apeptico Formerly VC-backed Vienna, Austria
Iovance Biotherapeutics Corporation San Carlos, CA
You’re viewing 5 of 65 competitors. Get the full list »

ImmusanT Patents

ImmusanT Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2020198434-A1 Use of il-2 for diagnosis of celiac disease Inactive 26-Mar-2019
WO-2019113037-A1 Measurement of ccl20 after gluten exposure Inactive 04-Dec-2017
AU-2018357840-A1 Dosing regimens for celiac disease Inactive 30-Oct-2017
CA-3080716-A1 Dosing regimens for celiac disease Inactive 30-Oct-2017
EP-3703728-A1 Dosing regimens for celiac disease Inactive 30-Oct-2017 A61K38/10
To view ImmusanT’s complete patent history, request access »

ImmusanT Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

ImmusanT Acquisitions (1)

ImmusanT’s most recent deal was a Merger/Acquisition with Nexpep (Discovery Platform). The deal was made on 15-Mar-2011.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Nexpep (Discovery Platform) 15-Mar-2011 Merger/Acquisition Drug Discovery
To view ImmusanT’s complete acquisitions history, request access »

ImmusanT FAQs

  • When was ImmusanT founded?

    ImmusanT was founded in 2010.

  • Where is ImmusanT headquartered?

    ImmusanT is headquartered in Cambridge, MA.

  • What is the size of ImmusanT?

    ImmusanT has 15 total employees.

  • What industry is ImmusanT in?

    ImmusanT’s primary industry is Drug Discovery.

  • Is ImmusanT a private or public company?

    ImmusanT is a Private company.

  • What is ImmusanT’s current revenue?

    The current revenue for ImmusanT is .

  • How much funding has ImmusanT raised over time?

    ImmusanT has raised $52.8M.

  • Who are ImmusanT’s competitors?

    Inovio Pharmaceuticals, Cognition Therapeutics, Sorrento Therapeutics, Apeptico, and Iovance Biotherapeutics are some of the 65 competitors of ImmusanT.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process